EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV)

International Journal of Gynecological Cancer

Volumn 14, Issue 2, 2004, Pages 360-365

  Ghaemmaghami, F ^a,c   Modares, M ^a   Arab, M ^a   Behtash, N ^a   Moosavi, A Z ^a   Khanafshar, N ^a   Hanjani, P ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ABINGTON MEMORIAL HOSPITAL   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapy; EMA EP; GTT; Toxicity

Indexed keywords

CISPLATIN; DACTINOMYCIN; ETOPOSIDE; METHOTREXATE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FEVER; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPOCALCEMIA; HYPOMAGNESEMIA; INFECTION; LEUKOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TROPHOBLASTIC TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DACTINOMYCIN; ETOPOSIDE; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PREGNANCY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 2042496280     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.014222.x     Document Type: Article

References (20)

1. Kohorn EI. The New FIGO 2000 Staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int Gynecol Cancer 2001;11:73-7.
2. Nevin J, Silcocks P, Hancock B, Coleman R, Nakielny R, Lorigan P. Guidelines for the stratification of patients recruited to trials of therapy for low-risk gestational trophoblastic tumor. Gynecol Oncol 2000;78:92-6.
3. Disaia PJ, Creasman WT. Clinical Gynecologic Oncology, 6th edn. St Louis: Mosby, 2002.
4. Cunningham FC, Gant NF, Leveno HJ, Gilstrap LC et al. Williams Obstetrics, 21st edn. New York: Mc Graw-Hill, 2001.
5. Berek JS, Hacker NF. Practical Gynecologic Oncology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 1999.
6. Berek JS. Novak's Gynecology, 13th edn. Philadelphia: Lippincott Williams & Wilkins, 2002.
7. Alici S, Eralp Y, Saip P et al. Clinical characteristics of gestational trophoblastic disease at a single institute. Tohoku J Exp Med 2002;197:95-100.
8. Termrungruanglert W, Kudelka AP, Piamsomboon S et al. Remission of refractory gestational trophoblastic disease with high dose Paclitaxel. Anticancer Drugs 1996;7:503-6.
9. Muggia DFM, Eifel PJ, Burkel TW. Cancer Principles and Practice, 6th edn. Philadelphia: Lippincott, 2001.
10. Newlands ES, Bower M, Holden L, Short D, Seckl Mj, Rustin Gj, Begent RH. Management of resistant gestational trophoblastic tumor. Reprod Med 1998;43:111-8.
11. Deppe G, Baker VV. Gynecologic Oncology Principles and Practice of Chemotherapy. London: Arnold, 1999.
12. Newlands ES, Bagshawe KD, Bergent RH et al. Results with EMA-CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, Vincristine) regimen in high-risk gestational trophoblastic tumors, 1979-1989. Br J Obstet Gynaecol 1991;98:550-7.
13. Bolis G, Bonazzi C, Lendori F et al. EMA-CO regimen in high risk gestational trophoblastic tumor (GTT). Gynecol Oncol 1988;31:439-44.
14. Schink JC, Singh DK, Rademaker AW et al. Etoposide, methotrexate, Actinomycin D, cyclophosphamide and vincristine for the treatment of metastatic high-risk gestational trophoblastic disease. Obstet Gynecol 1992;80:817-20.
15. Soper JT, Evans AC, Clarke-pearson Di et al. Alternating weekly chemotherapy with etoposide, methotrexate, dactinomycin/cyclophosphamide, vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol 1994;83:113-7.
16. Newlands ES, Bagshawe KD, Bergent RH et al. Developments in chemotherapy for medium and high risk patients with gestational trophoblastic tumors, 1979-84. Br J Obstet Gynaecol 1986;93:63-9.
17. Surwit EA, Childers JA. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen. J Reprod Med 1991;36:45-8.
18. Kim SJ, Bae SN, Kim CT, Han KT, Lee JM, Jung JK. Effects of multi-agent chemotherapy and independent risk factors in the treatment of high risk GTT - 25 years experiences of KRI-TRD. Int J Gynecol Obstet 1998;60:85-96.
19. Newlands ES, Mulholland PJ, Holden L, Seckl Mj, Rustin Gj. Etoposide and Cisplatin/Etoposide, Methotrexate and Actinomycin D (EMA) chemotherapy for patients with high risk gestational trophoblastic tumors refractory to EMA/Cyclophosphamide and Vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Clin Oncol 2000;18:854-9.
20. Kyoung J. Management of high risk gestational trophoblastic disease. J Reprod Med 43:1998.